Menu

Skip to content

For patients
MARK53 Knowledge
Mark53 Studies
Press review
MARK53-findings
- MARK53-Board
- MARK53 affiliated doctors
About us
- Contact
- Press kit
Request Mark53

Cancer therapy: more efficient – less side effects

Press review 2002

“Wenn ein Gen-Gendarm wehrlos ist” – mehr lesen
Die Presse, 15. Oktober 2002

Deutsch
English

ABOUT

With the Mark53 analysis, our company is making available a precise p53 gene test, which – for the first time – establishes the prerequisites for a broad clinical application of this biomarker. For the question, as to which patient responds to a cancer therapy and which does not, is a crucial one! We wish to pave the way for an efficient cancer therapy and continue to guarantee research that is independent of the pharmaceutical industry.

For patients
MARK53 Knowledge
Mark53 Studies
Press review
MARK53-findings
- MARK53-Board
- MARK53 affiliated doctors
About us
- Contact
- Press kit
Request Mark53

Contact
Imprint
Partners

© 2013–2022 p53 research. All rights reserved